We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Federal Circuit Rules for Pfizer in Suit Vs. Ranbaxy

Law360 (December 29, 2003, 12:00 AM EST) -- The Court of Appeals for the Federal Circuit last week upheld a preliminary injunction barring India’s Ranbaxy Pharmaceuticals from marketing a generic version of Pfizer's Vantin antibiotic, Pfizer said.

The court affirmed a lower court ruling by the U.S. District Court of New Jersey. In addition, it decided in Pfizer's favor on a cross-appeal of the amount of bond the company is obligated to post in the case. The determination of bond was remanded to the district court with instructions to reduce the $15 million it...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.